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ABSTRACT  
The objective of the work is to try and assess the applicability and manufacturing possibilities to optimize an enteric coate d tablet formulation 
containing Rabeprazole sodium as the drug aiming at the anti-acidity activity with desired drug release properties. Enteric coated tablet was 
chosen as dosage form being a cost-effective technology for pharmaceutical industry requiring fewer procedures. Before the implementation of 
the pharmaceutical technological aims, analysis of critical factors influencing the manufacture was carried out. Reproducible  manufacturing 
processes are required to achieve suitability and tablets uniformity to achieve the uniform properties of tablets, which could influence 
experimental parameters. Rabeprazole in core content of tablet is blended with HPMC (different grades), xanthan gum, PVPK30, mannitol, 
crosspovidone, Sodium starch glycolate, Colloidal silicon dioxide to formulate the product. Prepared formulation was tested for weight and 
content uniformity, physical characteristics, in vitro dissolution behaviour, acid resistance and accelerated stability studies. All studies 
performed resulted and revealed for assurance of such enteric coated tablet formulation for drug Rabeprazole with optimum characteristics, 
concluding it as a promising approach to enhance drug release characteristics.  
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1. INTRODUCTION 
Oral site-specific drug delivery systems have attracted a 
great deal of interest recently for the local treatment of a 
variety of bowel diseases and also for improving systemic 
absorption of drugs, which are unstable in the stomach. 
However, the micro environment in the gastrointestinal tract 
and varying absorption mechanisms generally causes 
hindrance for the formulation scientist in the development 
and optimization of oral drug delivery.1 Delivery of 
therapeutic agent into the intestinal region could be 
accomplished by the application of an enteric coating on a 
solid dosage form. Several approaches have been attempted 
and reported during the last decade to develop new 
methodologies for site-specific drug release, including pH-
sensitive drug release and time-controlled drug release. 
Among these, the time-controlled release systems such as 
sustained or delayed-release dosage forms are very 
promising. Nevertheless, due to the potentially large 
variation of gastric emptying time of dosage forms in 
humans, these dosage form may show high inter patient 
variability in the site of drug delivery. On the other hand, pH-
sensitive delivery systems such as enteric-coated dosage 
forms offer a simple and practical means for intestinal drug 
delivery. Rabeprazole sodium2   is a classical example of 
proton pump inhibitors and is approved by FDA for the 
treatment of symptomatic gastro esophageal reflux disease, 
long-term treatment and maintenance of erosive esophagitis. 
The stability of Rabeprazole sodium decreases with a 
corresponding decrease in the pH of the media. Hence, the 
exposure of Rabeprazole sodium to the acidic contents of the 
stomach would lead to significant degradation of the drug 
and would result in reduced bioavailability. Few attempts 
have been made to deliver this drug by peroral route in the 
form of enteric coated granules, solid dispersion, and 
suspension and matrix tablets. A number of enteric coating 
polymers are available and capable of protecting the drug 
core from the aggressive environments of the stomach. Being 
soluble at higher pH values, these polymers dissolve in the 
intestine and release the core for ready action. These 
polymers include several synthetic polymers like cellulose 
acetate phthalate (CAP), hydroxy propyl methyl cellulose 
phthalate (HPMCP).  
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The aim of the present study was to compare the suitability 
of these renowned polymers to develop enteric coated 
tablets3 of a very sensitive proton pump inhibitor 
Rabeprazole sodium. Rabeprazole sodium drug is a sodium 
salt of 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl) 
methylsulfinyl) -1H-benzo[d] imidazole belongs to a class of 
proton pump inhibitors (PPIs). It suppress   surface of the 
gastric parietal cell. Enteric coated tablets are solid unit 
dosage forms meant for oral administration and are designed 
to bypass the stomach.4 
2. MATERIALS AND METHODS 
Rabeprazole sodium is used as API in this study and was 
obtained as a gift sample from Incare Pharma Pvt. Ltd; 
hydroxy propyl methyl cellulose grade K15 and K100, 
xanthan gum, PVPK30, mannitol, crosspovidone, Sodium 
starch glycolate, Colloidal silicon dioxide are the other 
ingredients used for formulation of enteric coated tablets. 
Preliminary and optimization experiments have been carried 
out. Principal aim of the research work was the optimization 
of enteric coated tablet. The methods section contains all 
method descriptions, which were used either during 
preliminary or optimization studies. 
2.1 Pre-formulation Studies5,6    
The objective of pre-formulation studies is to develop a 
portfolio of information about the drug substance to serve as 
a set of parameters against which detailed formulation 
design can be carried out. Pre-formulation investigations are 
designed to identify those physicochemical properties of 
drug substances and excipients that may influence the 
formulation design, method of manufacture, and 
biopharmaceutical properties of the resulting product. 
Analysis of lubricated compression blend for pre 
compression parameters such as angle of repose, bulk and 
tapped densities, compressibility index, and Hausner ratio 
was done according to the procedure stated for 
characterization of Rabeprazole. 
2.2 Fourier transforms infrared spectroscopy (FT-IR) 
interpretation 7,8,9,10  
The infrared spectrum of rabeprazole was recorded by using 
Perkin Elmer (Spectrum Bx) Fourier transform infrared 
spectroscopy. The sample was placed on the sample holder. 
The surface of the sample levelled. This sample holder was 
then placed in the analysis chamber and the spectrum was 
recorded.  
2.3 Formulation batches11,12,13,14  
Different formulation batches were formulated containing 
Rabeprazole as the active ingredient along with other 
suitable ingredients as tabulated below in table 1. Various 
blends tried were named as Batch B1 to B9. 
 
 
Table 1. Formulation of core tablet 
S. No. INGREDIENT B1 B2 B3 B4 B5 B6 B7 B8 B9 
1. Rabeprazole sodium 20 20 20 20 20 20 20 20 20 
2. HPMC K-100 20 - - 30 - - 15.5 - - 
3. HPMC K-15 - 20 - - 30 - - 15.5 - 
4. Xanthan gum - - 20 - - 30 - - 15.5 
5. Mannitol 60.4 60.4 60.4 50.4 50.4 50.4 65.4 65.4 65.4 
6. Crospovidone 30 30 30 30 30 30 30 30 30 
7. Providone (PVP-K30) 12 12 12 12 12 12 12 12 12 
8. Talc 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
9. Magnesium stearate 5 5 5 5 5 5 5 5 5 
10. Sodium starch glycolate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
11. Colloidal silicon dioxide 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
2.4 Procedure of granulation13  (For batches B1 – 
B9)  
Granules of the sustained release layer were formulated 
with dry granulation method using PVP K30 as 
granulating agent. Rabeprazole & polymer were passed 
through 40# s.s. sieve.  Mixed well for 15-20 minutes. 
PVP K30 was added to sufficient water under stirring to 
prepare granulating solution. This granulation solution 
was added to drug mixture till good wet mass was 
formed. This mass was passed through 8# s.s. sieve. 
These granules were dried till LOD (loss on drying) was 
2.0 – 2.5%  and dried granules were passed through 20# 
sieve and the granules were lubricated with magnesium 
stearate and HPMC K-15, HPMC K100 , Xanthum gum 
was also added in this step which were passed through 
60# sieve prior to addition to granules.  
 
Table  2. Formulation of enteric coated tablet 
S. No. INGREDIENT B1 B2 B3 B4 B5 B6 B7 B8 B9 
1. HPMC-P 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 
2. Triethyl citrate (5%) 0.76 0.76 0.76 0.76 0.76 0.76 0.76 0.76 0.76 
3. Isopropyl alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s 
4. Dichloro- methane q.s q.s q.s q.s q.s q.s q.s q.s q.s 
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2.5 Procedure for preparation of sub-coating of the core 
tablets12 
Sub coating of the compressed tablets is achieved by 
standard coating pan technique. Coating solutions of 
OPADRY prepared separately with plasticizers in 5 % 
concentrations respectively. Thus solutions are applied over 
tablets using spray gun at appropriate pressure. The coated 
tablets are dried at 35-40oC for 10min. 1%, 2%, 3%, and 4% 
of sub coating percentage has been given to the core tablet. 
2.6 Procedure for preparation of enteric coating of the 
sub-coated tablets11 
The sub coated tablets are loaded into containing bed is 
warmed till the temperature reaches to 380C - 400C. Then 
spray gun is switched on to spray the enteric coating 
dispersion using HPMC-P in more than 8% of enteric coating 
percentage has been given to the sub coated tablets. 
2.7 Evaluation of lubricated blends of formulations 
2.7.1 Pre-compression parameters of tablet9 
Analysis of lubricated compression blend for 
precompression parameters such as angle of repose, bulk 
and tapped densities, compressibility index, and Hausner 
ratio was done according to the procedure stated for 
characterization of Rabeprazole sustained release tablets. 
2.7.2 Post-compression parameters 15,16,17,18  
The tablet compacts were tested for Description, Thickness, 
Hardness, Friability,  Weight variation, Uniformity of drug 
content, In-vitro drug release of enteric coated tablets, Drug 
Release Kinetic Studies, Accelerated Stability Studies. The 
results obtained are elaborated in the next section. 
3. RESULTS AND DISCUSSION  
3.1 Pre-formulation study of the drug 
The flow property study of blend of all ingredients along 
with drug was carried out & all the parameters obtained 
within a range. 
Table 3. Micromeretic properties of API 
S. No. Characteristics Results 
1 Description 
Of white to pale yellow colour 
amorphous powder 
2 Bulk Density 0.53gm/ml 
3 Tapped Density 0.69gm/ml 
4 Carr’s Index 32.1% 
5 Hausner Ratio 4.17 
6. Angle of Response 36 
 
3.2 Compatibility Study 
The results of FTIR analysis of pure drug and bend of drug 
with polymers used for the formulations were interpreted 
and revealed that there is no significant interaction between 
drug and polymers. This is an assuring result to use these 
ingredients with no alteration in physicochemical as well as 
therapeutic activity of the formulation. The Rabeprazole 
FTIR alone and in blend is presented as below in figures 1 to 
4.
 
 
Fig. 1 FT-IR of Rabeprazole 
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Fig. 2 FT-IR of Rabeprazole with HPMC K100 
 
Fig. 3 FT-IR of Rabeprazole with xanthan gum 
 
Fig. 4 FT-IR of Rabeprazole with HPMC K-15 
 
3.3 Post Compressional evaluation of prepared tablets  
Formulation batches B1 to B9 were evaluated for post 
compressional parameters such as Weight, Thickness, 
Hardness, Friability and the results found are as tabulated 
below in table 4. Results obtained of all formulation within 
range as per official standard. 
 
Table  4. Characteristics of formulation 
Formulation 
Batch 
Average wt (mg) 
± (SD) 
Thickness (m) 
± (SD) 
Hardness (kp) 
± (SD) 
Friability 
± (SD) 
B1 151.2 ± 5.16 4.0 ± 0.08 6 – 8± 0.18 
 
0.75± 0.08 
 
B2 149.5 ± 5.11 4.1 ± 0.08 
 
6 – 8± 0.18 
 
0.75± 0.08 
 
B3 150.6 ± 5.09 
 
4.0 ± 0.07 
 
6 – 8± 0.28 
 
0.64± 0.08 
 
B4 151.4 ± 5.12 
 
4.0 ± 0.08 
 
6 – 8± 0.18 
 
0.75± 0.08 
 
B5 144 ± 5.15 4.1 ± 0.08 
 
6 – 8± 0.22 
 
0.60± 0.08 
 
B6 152.6 ± 5.16 4.1 ± 0.08 
 
6 – 8± 0.23 
 
0.65± 0.08 
B7 150 ± 5.17 4.0 ± 0.08 
 
6 – 8± 0.31 
 
0.71± 0.08 
B8 145 ± 5.12 4.0 ± 0.08 
 
6 – 8± 0.23 
 
0.74± 0.08 
B9 149 ± 5.10 4.0 ± 0.08 
 
6 – 8± 0.33 
 
0.75± 0.08 
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3.4 Acid resistance test19 
To determine the effect of gastric environment the acid 
resistance study was carried out. All the formulation showed 
resistance to acid. Formulations maintained their integrity in 
simulated gastric fluid. The formulations didn’t disintegrate 
up to 45 min as per the official standard.  
 
Table  5. Acid resistance test 
Batch B1 B2 B3 B4 B5 B6 B7 B8 B9 
Acid resistance (%) 100 95 98 93 99.5 90 98.8 80 97 
Disintegration of tablet in acid 
0.1 N HCL(1hr) 
NO NO NO NO NO NO NO NO NO 
 
3.5 In vitro Dissolution tests20,21,22  
The dissolution for all the formulations was carried out 
according to US Pharmacopoeia for 2 h in 0.1N HCl and then 
media was changed into phosphate buffer of pH 6.8. The 
temperature was maintained at 37 ± 0.5°C and a constant 
paddle rotation speed of 100 rpm. The formulation B1 
showed more percentage drug release (99.5%) as compared 
with other formulation. All the formulations showed 
optimum drug release as per the criteria of sustained drug 
release. From the results of the present study experiment, it 
was concluded that by using the combination of HPMC K15 
and HPMC K100, one can obtain the good control on the 
release profile of water soluble drug and sustained release 
formulation can be successfully prepared. HPMC K100 
hydrates and forms gel at a higher rate as compared to 
HPMC K15 and is helpful for initially controlling the release 
rate of water soluble Rabeprazole sodium drug. 
Table 6 depicts results of in vitro dissolution test. The in vitro 
drug release profiles B1 to B9 are diagrammed below in 
figures 5 to 7. 
 
Table  6.  In vitro drug release from the formulations B1 to B9 
In vitro drug release from 
the formulation after 
time(hrs) 
                                              BATCH  
B1 B2 B3 B4 B5 B6 B7 B8 B9  
0 00 00 00 00 00 00 00 00 00 
1 5.3 5.22 5.21 5.2 5.18 5.21 5.21 5.21 5.21  
1.30 20 15 10 16 13 12 13 16 14  
2 35.1 31 27 30 25 21 30 24 25  
3 46.96 40.05 35.35 39 33.65 30 40 38 35  
4 56.17 49.81 46.08 50 42 37 55 53 51  
5 65.8 58 53.66 59 51 45 60 63.66 63.66  
6 74 65 60.89 67 58 53 70.89 70.89 70.89  
7 80 71 70.3 71 64 60 73 75.3 73  
8 87.4 78 76 76 68 70 80 82.21 81  
9 91 83 80 80 73 79 82 86.29 86.29 
10 94 85.7 85 83 80 84 85 90 88.29 
11 97 91 90.1 88 85.25 88 90.1 95 90.1 
12 99.5 95.2 93.2 92 91 89 96.7 98.1 96.7 
 
 
Fig. 5 In vitro drug release profile of batches (B1-B3) 
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Fig. 6 In vitro drug release profile of batches (B4-B6) 
 
 
Fig. 7 In vitro drug release profile of batches (B7-B9) 
 
3.6 Stability study23,24     
In the present study, stability studies were carried out at 40 
 2 oC/ 75  5 % RH for a specific time period up to 1 month.  
The tablets from the selected and optimized batch (B-1) 
were studied for stability and kept under the accelerated 
conditions of temperature and moisture (humidity) for the 
period of one month. Each tablet was individually weighed 
and packed in high-density polyethylene (HDPE) containers 
and put at above specified conditioned in a Stability chamber 
for one month. After one month, the formulation was 
observed for changes in physical appearance and chemical 
analysis. The optimized formulation B1 showed very good 
drug release behaviour even after undergoing accelerated 
stability studies which conformed to its optimum nature. 
Data is tabulated in table 7. 
 
 
Fig. 8 Stability study curve 
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Table 7. Stability study of optimized batch (B1 ) in intestine PH (7.5) 
Sampling time (Hr) Colour change Thickness Change in integrity 
0 No 4.1 No 
2 No 4.3 No 
4 No 4.7 No 
6 No 4.8 No 
8 No 4.10 No 
10 No 4.13 No 
12 No 4.15 No 
 
3.7 Drug Release Kinetic Studies  
To analyse the mechanism of drug release from the tablets, 
in vitro dissolution data were fitted in Zero Order, First 
Order, Matrix Model, Korsemeyer-Peppas Model. The results 
are as tabulated below in table 8. 
 
Table  8. Drug Release Kinetic Studies 
Formulation Batch 
(Optimized) 
Zero Order 
(R2) 
First Order 
(R2) 
Higuchi  Model 
(R2) 
Korsemeyer- 
Peppa’s Model (n) 
B1 0.9088 0.9612 0.9901 0.5345 
 
 
The batch B1 is optimized in that R2 values were higher for 
Higuchi model than for zero order model indicating that the 
drug release from the formulation followed Higuchi model, 
indicating that the drug release mechanism from the tablet 
was diffusion controlled. Obtained values of n is 0.5345 
indicating non-fickian release kinetic, which is indicating of 
drug release mechanism involving, diffusion mechanism. 
Therefore, the release of drug from the prepared tablet is 
controlled by swelling of polymers followed by drug 
diffusion through the swelled polymer. 
4. CONCLUSION 
In the above view of findings it can be concluded that 
hydroxypropylmethylcellulose of grade K100M when 
combined with the grade K15M shows the desired sustained 
release effect and hence can be utilized as matrix forming 
agent to prolong the release of Rabeprazole. The overall 
frequency of administration of a drug candidate like 
Rabeprazole was successfully reduced, which generally 
requires dosing in 3 to 4 times a day in conventional tablet 
dosage form. Thus the improved patient compliance might 
be obtained by the administration of such a dosage form with 
the reduced dosing frequency and of attractive appearance. 
The release retardant materials are economical, readily 
available, safe, having wide regulatory acceptance and easy 
to handle. It may be beneficial to adopt such a technology for 
the commercial production of enteric coated sustained 
release tablet. 
From the results of the present study experiment, it was 
concluded that by using the combination of HPMC K15M and 
HPMC K100M, one can obtain the good control on the release 
profile of water soluble drug and sustained release 
formulation can be successfully prepared. HPMC K100M 
hydrates and forms gel at a higher rate as compared to HPMC 
K15M and is helpful for initial controlling the release rate of 
water soluble Rabeprazole sodium drug. In all formulations, 
batch B1 shows better drug release (99.5%) in which 
polymer HPMC K100M -20mg is added. 
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